ERS Research Seminar

New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

09 – 10 May 2019; Paris, France

Day 1 – Thursday, 09 May 2018

08:30-08:45: Registration
08:45-09:00: Introduction (Jacques Cadranal and Thierry Berghmans)

Session 1: From molecular alterations to cancer immunity in NSCLC

Chairs: P. Pauwels and T. Berghmans

09:00-09:25: What are the main mechanisms of oncogenic addiction? (Joanna Chorostowska, PL)
09:25-09:50: Are KRAS mutations druggable? (Marina Garassino, IT)
09:50-10:15: How does the cancer immunity circle operate (or dysoperate)? (Joachim Aerts, NL)

10:15-10:40: Panel discussion
10:40-11:00: Coffee break

Session 2: From molecular target to molecular resistance in NSCLC

Chairs: J. Aerts and D. Planchard

11:00-11:25: Molecular diagnosis for oncogenic addictions (Patrick Pauwels, BL)
11:25-11:50: When and how to identify resistance mechanisms to targeted therapies (Nicolas Girard, FR)
11:50-12:15: Predictive biomarker of immune checkpoint inhibitors efficacy (Luis Paz-Ares, SP)

12:15-12:40: Panel discussion
12:40-14:00: Lunch

14:00-15:30 Session 3: From molecular addiction to therapeutic strategy in NSCLC

Chairs: M. Garassino, J. Chorostowska

14:00-14:25: Therapeutic strategy for EGFR driven NSCLC (Jacques Cadranal, FR)
14:25-14:50: Therapeutic strategy for ALK/ROS driven NSCLC (Jan Van Meerbeeck, BL)
14:50-15:15: Therapeutic strategy for other oncogenic drivers (David Planchard, FR)

15:15-15:40: Panel discussion
15:40-16:00: Coffee break

16:00-17:45: Session 4 – Breakout – Difficult situations in the era of targeted therapies

Group 1. How to manage brain metastasis – chairs: L. Hendriks and T. Berghmans
Group 2. How to manage diagnostic resistance – chairs: J. Chorostowska and N. Girard
Group 3. How to manage specific toxicities of targeted therapies – chairs: A.M. Dingemans and D. Planchard

17:45-18:00: Urgent questions

From 19h00: Dinner
**Day 2 – Friday, 10 May 2018**

**Session 5: From PD1/PD-L1 monotherapy in selected patients to PD1/PD-L1 combo for all NSCLC**

**Chairs:** J. Van Meerbeeck anad J. Cadranel

09:00-09:20: From anti-PD1/L1 inhibitors to new immunotherapies (Thierry Berghmans, BL)
09:20-09:40: Which immunotherapy for which patients? (Lizza Hendriks, NL)
09:40-10:00: Combination therapy in the era of immunotherapy (Anne-Marie Dingemans, NL)

10:00-10:15: *Panel discussion*

10:15-10:45: *Coffee break*

**Session 6: General podium discussion on research priorities**

**Chairs:** J. Cadranel and T. Berghmans

10:45-11:45: Summary of working groups: 15’ per group
11:45-12:30: Whole faculty and all participants

12:30-14:00: *Lunch and departure*